163 related articles for article (PubMed ID: 15557204)
1. Self-reactive T cell receptor-reactive CD8+ T cells inhibit T cell lymphoma growth in vivo.
Gonthier M; Llobera R; Arnaud J; Rubin B
J Immunol; 2004 Dec; 173(11):7062-9. PubMed ID: 15557204
[TBL] [Abstract][Full Text] [Related]
2. Direct visualization of cross-reactive effector and memory allo-specific CD8 T cells generated in response to viral infections.
Brehm MA; Markees TG; Daniels KA; Greiner DL; Rossini AA; Welsh RM
J Immunol; 2003 Apr; 170(8):4077-86. PubMed ID: 12682237
[TBL] [Abstract][Full Text] [Related]
3. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
4. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
5. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope.
Otahal P; Hutchinson SC; Mylin LM; Tevethia MJ; Tevethia SS; Schell TD
J Immunol; 2005 Jul; 175(2):700-12. PubMed ID: 16002665
[TBL] [Abstract][Full Text] [Related]
6. TCR vaccines against a murine T cell lymphoma: a primary role for antibodies of the IgG2c class in tumor protection.
Lambert SL; Okada CY; Levy R
J Immunol; 2004 Jan; 172(2):929-36. PubMed ID: 14707065
[TBL] [Abstract][Full Text] [Related]
7. Flow-microfluorometric monitoring of oligoclonal CD8+ T cell responses to an immunodominant Moloney leukemia virus-encoded epitope in vivo.
Brawand P; Biasi G; Horvath C; Cerottini JC; MacDonald HR
J Immunol; 1998 Feb; 160(4):1659-65. PubMed ID: 9469422
[TBL] [Abstract][Full Text] [Related]
8. Dramatic influence of V beta gene polymorphism on an antigen-specific CD8+ T cell response in vivo.
Bour H; Michielin O; Bousso P; Cerottini JC; MacDonald HR
J Immunol; 1999 Apr; 162(8):4647-56. PubMed ID: 10202004
[TBL] [Abstract][Full Text] [Related]
9. IL-2-activated CD8+CD44high cells express both adaptive and innate immune system receptors and demonstrate specificity for syngeneic tumor cells.
Dhanji S; Teh HS
J Immunol; 2003 Oct; 171(7):3442-50. PubMed ID: 14500639
[TBL] [Abstract][Full Text] [Related]
10. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice.
Staveley-O'Carroll K; Schell TD; Jimenez M; Mylin LM; Tevethia MJ; Schoenberger SP; Tevethia SS
J Immunol; 2003 Jul; 171(2):697-707. PubMed ID: 12847236
[TBL] [Abstract][Full Text] [Related]
11. Self-antigen maintains the innate antibacterial function of self-specific CD8 T cells in vivo.
Dhanji S; Chow MT; Teh HS
J Immunol; 2006 Jul; 177(1):138-46. PubMed ID: 16785508
[TBL] [Abstract][Full Text] [Related]
12. Anti-Gag cytolytic T lymphocytes specific for an alternative translational reading frame-derived epitope and resistance versus susceptibility to retrovirus-induced murine AIDS in F(1) mice.
Mayrand SM; Healy PA; Torbett BE; Green WR
Virology; 2000 Jul; 272(2):438-49. PubMed ID: 10873788
[TBL] [Abstract][Full Text] [Related]
13. Class Ia MHC-deficient BALB/c mice generate CD8+ T cell-mediated protective immunity against Listeria monocytogenes infection.
D'Orazio SE; Halme DG; Ploegh HL; Starnbach MN
J Immunol; 2003 Jul; 171(1):291-8. PubMed ID: 12817010
[TBL] [Abstract][Full Text] [Related]
14. Perforin-deficient CD8+ T cells provide immunity to Listeria monocytogenes by a mechanism that is independent of CD95 and IFN-gamma but requires TNF-alpha.
White DW; Harty JT
J Immunol; 1998 Jan; 160(2):898-905. PubMed ID: 9551927
[TBL] [Abstract][Full Text] [Related]
15. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2000 Jan; 164(2):916-25. PubMed ID: 10623840
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
Winter H; Hu HM; McClain K; Urba WJ; Fox BA
J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
[TBL] [Abstract][Full Text] [Related]
17. Contemporary analysis of MHC-related immunodominance hierarchies in the CD8+ T cell response to influenza A viruses.
Belz GT; Stevenson PG; Doherty PC
J Immunol; 2000 Sep; 165(5):2404-9. PubMed ID: 10946264
[TBL] [Abstract][Full Text] [Related]
18. Adaptive immunity and enhanced CD8+ T cell response to Listeria monocytogenes in the absence of perforin and IFN-gamma.
Badovinac VP; Harty JT
J Immunol; 2000 Jun; 164(12):6444-52. PubMed ID: 10843700
[TBL] [Abstract][Full Text] [Related]
19. Self-thyroid epithelial cell (TEC)-reactive CD8+ T cell lines/clones derived from autoimmune thyroiditis lesions. They recognize self-thyroid antigens directly on TEC to exhibit T helper cell 1-type lymphokine production and cytotoxicity against TEC.
Sugihara S; Fujiwara H; Niimi H; Shearer GM
J Immunol; 1995 Aug; 155(3):1619-28. PubMed ID: 7543527
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the Fas ligand/Fas-dependent apoptosis of antiretroviral, class I MHC tetramer-defined, CD8+ CTL by in vivo retrovirus-infected cells.
Rich RF; Green WR
J Immunol; 2002 Mar; 168(6):2751-8. PubMed ID: 11884442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
